Scoop: AbbVie drops IBS drug Viberzi in Canada, 'devastating' patients
Sam was 19 years old when she was diagnosed with irritable bowel syndrome with diarrhea, or IBS-D. She quickly learned that it’s a much more painful condition than most people realize.
At the time of her diagnosis, Sam was dangerously underweight because her body couldn’t absorb nutrients. She’d wake up at 5 am in agony. And she was always looking for the nearest bathroom, which made going to new places nerve-wracking.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.